122 related articles for article (PubMed ID: 37462959)
21. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
[TBL] [Abstract][Full Text] [Related]
22. Pathological and 3 Tesla Volumetric Magnetic Resonance Imaging Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
Tan N; Shen L; Khoshnoodi P; Alcalá HE; Yu W; Hsu W; Reiter RE; Lu DY; Raman SS
J Urol; 2018 May; 199(5):1218-1223. PubMed ID: 29128577
[TBL] [Abstract][Full Text] [Related]
23. Role of multiparametric magnetic resonance imaging to predict postoperative Gleason score upgrading in prostate cancer with Gleason score 3 + 4.
Kim H; Kim JK; Hong SK; Jeong CW; Ku JH; Kwak C
World J Urol; 2021 Jun; 39(6):1825-1830. PubMed ID: 32869150
[TBL] [Abstract][Full Text] [Related]
24. Combination of prostate imaging reporting and data system (PI-RADS) score and prostate-specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients.
Washino S; Okochi T; Saito K; Konishi T; Hirai M; Kobayashi Y; Miyagawa T
BJU Int; 2017 Feb; 119(2):225-233. PubMed ID: 26935594
[TBL] [Abstract][Full Text] [Related]
25. Pre-biopsy 3-Tesla MRI and targeted biopsy of the index prostate cancer: correlation with robot-assisted radical prostatectomy.
Patel U; Dasgupta P; Challacombe B; Cahill D; Brown C; Patel R; Kirby R
BJU Int; 2017 Jan; 119(1):82-90. PubMed ID: 27153933
[TBL] [Abstract][Full Text] [Related]
26. 3T multiparametric MR imaging, PIRADSv2-based detection of index prostate cancer lesions in the transition zone and the peripheral zone using whole mount histopathology as reference standard.
Asvadi NH; Afshari Mirak S; Mohammadian Bajgiran A; Khoshnoodi P; Wibulpolprasert P; Margolis D; Sisk A; Reiter RE; Raman SS
Abdom Radiol (NY); 2018 Nov; 43(11):3117-3124. PubMed ID: 29725743
[TBL] [Abstract][Full Text] [Related]
27. Clinically insignificant prostate cancer suitable for active surveillance according to Prostate Cancer Research International: Active surveillance criteria: Utility of PI-RADS v2.
Yim JH; Kim CK; Kim JH
J Magn Reson Imaging; 2018 Apr; 47(4):1072-1079. PubMed ID: 28901655
[TBL] [Abstract][Full Text] [Related]
28. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy.
Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S
World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717
[TBL] [Abstract][Full Text] [Related]
29. Structured approach to resolving discordance between PI-RADS v2.1 score and targeted prostate biopsy results: an opportunity for quality improvement.
Arcot R; Sekar S; Kotamarti S; Krischak M; Michael ZD; Foo WC; Huang J; Polascik TJ; Gupta RT
Abdom Radiol (NY); 2022 Aug; 47(8):2917-2927. PubMed ID: 35674785
[TBL] [Abstract][Full Text] [Related]
30. A comprehensive comparison between mpMRI of the prostate, MR-US fusion biopsy and whole mount histopathology.
Doblhammer S; Kinger P; Starmuehler M; Muschitz C; Schima W; Susani M; Baierl A; Broessner C
World J Urol; 2023 Apr; 41(4):1055-1060. PubMed ID: 36840753
[TBL] [Abstract][Full Text] [Related]
31. Effect of observation size and apparent diffusion coefficient (ADC) value in PI-RADS v2.1 assessment category 4 and 5 observations compared to adverse pathological outcomes.
Abreu-Gomez J; Walker D; Alotaibi T; McInnes MDF; Flood TA; Schieda N
Eur Radiol; 2020 Aug; 30(8):4251-4261. PubMed ID: 32211965
[TBL] [Abstract][Full Text] [Related]
32. Prostate MRI percentage tumor involvement or "PI-RADS percent" as a predictor of adverse surgical pathology.
Ratnani P; Dovey Z; Parekh S; Sobotka S; Shukla D; Davis A; Roshandel R; Wagaskar V; Jambor I; Lundon DJ; Wiklund P; Kyprianou N; Menon M; Tewari A
Prostate; 2022 Jun; 82(9):970-983. PubMed ID: 35437769
[TBL] [Abstract][Full Text] [Related]
33. Does the Prostate Imaging-Reporting and Data System (PI-RADS) version 2 improve accuracy in reporting anterior lesions on multiparametric magnetic resonance imaging (mpMRI)?
Hoffmann R; Logan C; O'Callaghan M; Gormly K; Chan K; Foreman D
Int Urol Nephrol; 2018 Jan; 50(1):13-19. PubMed ID: 29188489
[TBL] [Abstract][Full Text] [Related]
34. Prostate cancer detection rate in men undergoing transperineal template-guided saturation and targeted prostate biopsy.
Kaufmann B; Saba K; Schmidli TS; Stutz S; Bissig L; Britschgi AJ; Schaeren E; Gu A; Langenegger N; Sulser T; Eberli D; Keller EX; Hermanns T; Poyet C
Prostate; 2022 Feb; 82(3):388-396. PubMed ID: 34914121
[TBL] [Abstract][Full Text] [Related]
35. 1.5-T multiparametric MRI using PI-RADS: a region by region analysis to localize the index-tumor of prostate cancer in patients undergoing prostatectomy.
Reisæter LA; Fütterer JJ; Halvorsen OJ; Nygård Y; Biermann M; Andersen E; Gravdal K; Haukaas S; Monssen JA; Huisman HJ; Akslen LA; Beisland C; Rørvik J
Acta Radiol; 2015 Apr; 56(4):500-11. PubMed ID: 24819231
[TBL] [Abstract][Full Text] [Related]
36. Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance.
Alanee S; Deebajah M; Dabaja A; Peabody J; Menon M
Int Urol Nephrol; 2022 Apr; 54(4):799-803. PubMed ID: 35138582
[TBL] [Abstract][Full Text] [Related]
37. Combining prostate health index and multiparametric magnetic resonance imaging in estimating the histological diameter of prostate cancer.
Hsieh PF; Li TR; Lin WC; Chang H; Huang CP; Chang CH; Yang CR; Yeh CC; Huang WC; Wu HC
BMC Urol; 2021 Nov; 21(1):161. PubMed ID: 34801024
[TBL] [Abstract][Full Text] [Related]
38. A magnetic resonance imaging-based nomogram for predicting clinically significant prostate cancer at radical prostatectomy.
Castellani D; Cecchini S; Mazzucchelli R; Soraci L; Di Rosa M; Fabbietti P; Palagonia E; Puccio F; Carnevali F; Paci E; Montironi R; Galosi AB
Urol Oncol; 2022 Aug; 40(8):379.e1-379.e8. PubMed ID: 35662497
[TBL] [Abstract][Full Text] [Related]
39. The combination of prostate imaging reporting and data system version 2 (PI-RADS v2) and periprostatic fat thickness on multi-parametric MRI to predict the presence of prostate cancer.
Cao Y; Cao M; Chen Y; Yu W; Fan Y; Liu Q; Gao G; Zhao Z; Wang X; Jin J
Oncotarget; 2017 Jul; 8(27):44040-44049. PubMed ID: 28476042
[TBL] [Abstract][Full Text] [Related]
40. Comparison of multiparametric and biparametric MRI of the prostate: are gadolinium-based contrast agents needed for routine examinations?
Junker D; Steinkohl F; Fritz V; Bektic J; Tokas T; Aigner F; Herrmann TRW; Rieger M; Nagele U
World J Urol; 2019 Apr; 37(4):691-699. PubMed ID: 30078170
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
